Boosting Antibiotic Research, Development Pipeline Critical To Ending Drug Resistance

The Guardian: Antibiotic resistance is a growing menace — we must act before it’s too late
John McConnell, editor of The Lancet Infectious Diseases

“…Profligate use of antibiotics has provided the evolutionary driver for bacteria to develop resistance to the drugs. Introduction of every new class of antibiotics has been followed by bacteria becoming resistant. … Ways to boost the research and development pipeline for new antibiotics are the focus of the latest report, released last week, from the Review on Antimicrobial Resistance (AMR), chaired by economist Jim O’Neill. … The latest paper suggests ways to revitalize the research and development pipeline to produce about 15 new licensed antibiotics every 10 years. … AMR will contribute to 10 million annual deaths worldwide by 2050, more even than cancer. By boosting the antibiotic pipeline — one of several measures needed to combat this crisis — we can start to take our fate into our own hands…” (5/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.